Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07733050) titled 'Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma' on July 23.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shanghai General Hospital, China
Condition:
Metastatic Pancreatic Ductal Adenocarcinoma
Intervention:
Drug: Serplulimab and Bevacizumab injection
Drug: FOLFIRINOX/NALIRIFOX
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollmen...